Bondrova 150 MG


Bondrova 150 MG


Stock Status:

In Stock

  • *Upload Prescription

    • (max file size 80 MB)



Ibandronic Acid



Ibandronic corrosive is shown for the treatment of postmenopausal osteoporosis, to diminish the hazard of fractures.

Treatment of Osteoporosis: Osteoporosis may be affirmed by the finding of moo bone mass (T-score <-2.0 SD) and the nearness or history of osteoporotic break, or a moo bone mass (T-score <-2.5 SD) within the nonattendance of recorded pre-existing osteoporotic break.


The pharmacodynamic activity of ibandronic etching is an obstacle to bone resorption. In vivo, the ibandronic sulphate prevents the pulverization of bone due to gonadal inactivation, retinoids, tumors, or neoplasms. In young (rapidly growing) mice, endogenous bone resorption was more impeded, resulting in increased bone mass compared with untreated organisms. Biological models suggest that the ibandronic sorbent can be an extremely potent inhibitor of osteoclast activity. In growing rats, there was indeed no evidence of demineralization at doses greater than 5,000 times the dose required to treat osteoporosis. The high potency and useful advantages of E-banding allow more adaptive dosing regimens and intermittent treatment with long drug-free periods at relatively low doses.

Corrosion Ibandronic can be an extremely potent bisphosphonate with a nitrogen-containing bisphosphonate position, acting on bone tissue and specifically blocking osteoclast activity. The specific action of ibandronic corrosion on bone tissue is based on this compound’s great preference for hydroxyapatite, which dictates the mineral structure of bone. Ibandronic corrosion reduces bone resorption without a synergistic effect on bone alignment. In postmenopausal women, it reduces bone turnover to premenopausal levels, resulting in a marked increase in bone mass. Day after day, or intermittent tissue erosion leads to decreased bone resorption, as evidenced by decreased serum and urine biochemical markers of bone remodeling, enlarged and decreased BMD. fracture frequency.


Dosage & Administration

The recommended dose of Ibandronic acid for treatment is one 150 mg film-coated tablet once a month. The tablet should preferably be taken on the same date each month. Ibandronic acid should be taken 60 minutes before the first food or drink (other than water) of the day or any other oral medication or supplementation (including calcium):

  • Tablets should be swallowed whole with a full glass of plain water (180 to 240 ml) while the patient is sitting or standing in an upright position. Patients should not lie down for 60 minutes after taking Ibandronic acid.
  • Plain water is the only drink that should be taken with Ibandronic acid. Please note that some mineral waters may have a higher concentration of calcium and therefore should not be used.
  • Patients should not chew or suck the tablet because of a potential for oropharyngeal ulceration. Patients should receive supplemental calcium or vitamin D if dietary intake is inadequate. In case a once-monthly dose is missed, patients should be instructed to take one Ibandronic Acid 150 mg tablet the morning after the tablet is remembered unless the time to the next scheduled dose is within 7 days. Patients should then return to taking their dose once a month on their originally scheduled date. If the next scheduled dose is within 7 days, patients should wait until their next dose and then continue taking one tablet once a month as originally scheduled. Patients should not take two 150 mg tablets within the same week.



It is likely that calcium supplements, gastric clarifiers, and some oral solutions containing polyvalent cations (such as aluminum, magnesium, press) have the potential to interfere with the absorption of Ibandronic Corrosive. Therefore, patients should wait 60 minutes after taking Ibandronic Corrosive some time after taking other verbal solutions. Considerations for pharmacokinetic interactions in postmenopausal women do not indicate any potential for interactions with tamoxifen or hormone replacement therapy (estrogen). No interactions have been observed with concomitant administration of melphalan/prednisolone in patients with different types of myeloma. In solid male volunteers and postmenopausal women, ranitidine etc. increased the bioavailability of corrode by about 20%, possibly due to a decrease in gastric causticity. However, because this increase is within the normal cycle of erosive Ibandronic bioavailability, no dosage modification is required when Ibandronic Corrosive is co-administered with H2 antagonists or other drugs that increase gastric pH. thick.
To me, no clinically significant smart sedation is considered likely, as the Ibandronic scavenger does not restrict the major human liver P450 isoenzymes and does not appear to initiate framework for cytochrome P450 in rat patients. In addition, plasma proteins are formally moo at restoring concentrations, and ibandronic corrodes in this way is unlikely to spit out other drugs. Corrosive ibandronic is killed by renal excretion, so to speak, and does not undergo any biological transformation. The secretory pathway does not appear to be associated with any known basic or acid transport frameworks involved in the excretion of other drugs. In a year, think of postmenopausal women with osteoporosis (BM16549). The incidence of upper gastrointestinal events in patients receiving concomitant headache medications or NSAIDs was comparable to that in patients receiving Ibandronic Corrosive 2.5 mg daily or 150 mg once monthly. Of the more than 1,500 patients selected for BM 16549 by comparing month-to-month erosive daily ibandronic dosing regimens, 14% of patients received a histamine (H2) blocker or a pump inhibitor. protons. Among these patients, the frequency of upper gastrointestinal events in patients treated with Ibandronic Corrosive 150 mg once a month was comparable to that in patients treated with Ibandronic Corrosive 2.5 mg daily.



Ibandronic Acid is contraindicated in patients sensitized to Ibandronic Acid or to any of the excipients. Ibandronic Acid is contraindicated in patients with uncorrected hypocalcaemia. As with all bisphosphonates indicated for the treatment of osteoporosis, pre-existing hypocalcaemia should be corrected recently when initiating treatment with Ibandronic Acid . As with some bisphosphonates, Ibandronic Acid is contraindicated in patients with esophageal malformations delaying esophageal emptying such as stenosis or achalasia. Ibandronic Acid is contraindicated in patients who are unable to stand or sit for at least 60 minutes.


Side Effects

The most side impacts of ibandronic corrosive are dyspepsia, queasiness, the runs, stomach torment, muscle hurts, migraines, tipsiness.


Pregnancy & Lactation

Pregnancy: Ibandronic Acid should not be used during pregnancy. There is no evidence that Acid ibandron has synergistic teratogenic or harmful fetal effects on rats and rabbits treated daily orally, and has no adverse effects on the enhancement of rat F1 sibs. The antagonistic effects of Acid ibandron on regenerative toxicity in rodents were observed with bisphosphonates as a lesson. They include reduced number of implant destinations, common transport resistance (dystocia) and increased visceral types (renal pelvic and ureteral diseases). No special consideration is given to the monthly system. Ibandronic Acid has no clinical involvement in pregnant women.

Nursing mothers: Ibandronic Acid should not be used during breastfeeding. Use 0.08 mg/kg/day IV in lactating rats. Ibandron is corrosive. The highest concentration of ibandron in breast drainage is 8.1 ng/ml and is observed within 2 hours after intravenous injection. Organization. After 24 hours, the concentration in the drainage fluid and plasma is compared to approximately 5% of the concentration measured after 2 hours.


Precautions & Warnings

Hypocalcaemia and other worrisome effects of the skeletal and mineral digestive system must have been sustained for some time by the initiation of Ibandronic Corrosion Treatment. Adequate calcium and vitamin D supplementation is mandatory in all patients. Oral bisphosphonates may cause discomfort near the upper gastrointestinal mucosa. Because of these possible worsening effects and the potential to reduce background infections, Ibandronic Corrosive should be used with caution in patients with active upper gastrointestinal tract problems (eg, or ulcers). Adverse events such as esophagitis, esophageal ulceration, and esophageal disintegration, which in some cases were severe and required hospitalization, and sometimes death, either by ligation or opening of the esophagus, have been detailed in this section. patients who accept bis phosphonate treatment. Extreme esophageal antagonism was found to be more common in patients who did not follow dosing instructions and/or who requested oral bisphosphonates after producing adverse events that indicated a condition esophagus gets worse. Patients should be specific and able to comply with prescribing information.
Physicians should be alert to any signs or side effects that signal a conceivable esophageal reaction, and patients should be educated to stop erosions and seek treatment in the event they produce modern dysphagia or gastroesophageal reflux disease. Although no increased risk has been observed in controlled clinical trials, there have been post-marketing reports of gastric and duodenal ulcers with the use of oral bisphosphonates, some of which extreme cases and complications. Since both NSAIDs and bisphosphonates have been associated with gastrointestinal disturbances, concomitant drug therapy with Ibandronic Corrosive should be used with caution. Osteoma of the jaw (ONJ) ​​has been detailed in patients treated with bisphosphonates. Most cases involve cancer patients undergoing dental procedures, but a few occur in patients with postmenopausal osteoporosis or other tests. ) and comorbid conditions (eg, emaciation, coagulopathy, bacterial infection, pre-existing dental infection). The most detailed cases involved patients treated with intravenous bisphosphonates, but a few involved patients treated orally. For patients whose jawbone is created while being treated with bisphosphonates, dental surgery may exacerbate the disease. For patients requiring dental procedures, there is no information to show whether discontinuation of bisphosphonates reduces the risk of ONJ. Clinical judgment by the attending physician should guide the management of each understanding based on an individual benefit and risk assessment.

Therapeutic Class

Bisphosphonate preparations


Storage Conditions

Keep underneath 30°C temperature, absent from light & dampness. Keep out of the reach of children.


Pharmaceutical Name

Healthcare Pharmaceuticals Ltd.